Dose Rates and Patient Contact Restrictions Following Zirconium-89 (Zr89) Positron Emission Tomography (PET) Studies

被引：0
|
作者：
Wright, G. [1 ]
Papadopoulos, E. [1 ]
Saleem, A. [1 ,2 ]
机构：
[1] Hull Univ Teaching Hosp NHS Trust, Cottingham, England
[2] Hull York Med Sch, Kingston Upon Hull, N Humberside, England
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-453
引用
收藏
页码：S223 / S223
页数：1
相关论文
共 50 条
  • [21] On the Versatility of Nanozeolite Linde Type L for Biomedical Applications: Zirconium-89 Radiolabeling and In Vivo Positron Emission Tomography Study
    Lacerda, Sara
    Zhang, Wuyuan
    de Rosales, Rafael T. M.
    Da Silva, Isidro
    Sobilo, Julien
    Lerondel, Stephanie
    Toth, Eva
    Djanashvili, Kristina
    ACS APPLIED MATERIALS & INTERFACES, 2022, 14 (29) : 32788 - 32798
  • [22] Investigation of 89Zr+4 chelation for positron emission tomography
    Chung, Aaron
    Abdalrahman, Mahmoud
    Barron, Brady
    Planalp, Roy
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 255
  • [23] Pilot study of humanized glypican-3-targeted zirconium-89 immuno-positron emission tomography for hepatocellular carcinoma
    Dickerson, Lindsay K.
    Lehnert, Adrienne L.
    Hamlin, Donald K.
    Labadie, Kevin P.
    Goodsell, Kristin E.
    Liu, Yongjun
    Li, Yawen
    Wilbur, D. Scott
    Miyaoka, Robert
    Park, James O.
    EJNMMI RESEARCH, 2024, 14 (01):
  • [24] Development of a method for the preparation of zirconium-89 radiolabelled chitosan nanoparticles as an application for leukocyte trafficking with positron emission
    Fairclough, M.
    Ellis, B.
    Boutin, H.
    Jones, A. K. P.
    McMahon, A.
    Alzabin, S.
    Gennari, A.
    Prenant, C.
    APPLIED RADIATION AND ISOTOPES, 2017, 130 : 7 - 12
  • [25] 89Zr-Immuno-Positron Emission Tomography in Oncology: State-of the-Art 89Zr Radiochemistry
    Heskamp, Sandra
    Raave, Rene
    Boerman, Otto
    Rijpkema, Mark
    Goncalves, Victor
    Denat, Franck
    BIOCONJUGATE CHEMISTRY, 2017, 28 (09) : 2211 - 2223
  • [26] Pilot study of zirconium-89 bevacizumab positron emission tomography for imaging angiogenesis in patients with inflammatory breast carcinoma receiving preoperative chemotherapy
    Jacene, H. A.
    Overmoyer, B.
    Schlosnagle, E. J.
    Abbott, A.
    Yeh, E.
    Paolino, J.
    Goel, S.
    Culhane, A.
    Bellon, J. R.
    Nakhlis, F.
    Hirshfield-Bartek, J.
    Van den Abbeele, A.
    CANCER RESEARCH, 2017, 77
  • [27] Effective dose to immuno-PET patients due to metastable impurities in cyclotron produced zirconium-89
    Alfuraih, Abdulrahman
    Alzirnami, Khalid
    Ma, Andy K.
    Alghamdi, Ali
    Al Jammaz, Ibrahim
    RADIATION PHYSICS AND CHEMISTRY, 2014, 104 : 145 - 149
  • [28] Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET
    Verel, I
    Visser, GWM
    Boerman, OC
    van Eerd, JEM
    Finn, R
    Boellaard, R
    Vosjan, MJWD
    Walsum, MSV
    Snow, GB
    van Dongen, GAMS
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2003, 18 (04) : 655 - 661
  • [29] Zirconium-89-Trastuzumab Positron Emission Tomography As a Tool to Solve a Clinical Dilemma in a Patient With Breast Cancer
    Gaykema, Sietske B. M.
    Brouwers, Adrienne H.
    Hovenga, Sjoerd
    Lub-de Hooge, Marjolijn N.
    de Vries, Elizabeth G. E.
    Schroder, Caroline P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (06) : E74 - E75
  • [30] Macrocycle-Based Hydroxamate Ligands for Complexation and Immunoconjugation of 89Zirconium for Positron Emission Tomography (PET) Imaging
    Boros, Eszter
    Holland, Jason P.
    Kenton, Nathaniel
    Rotile, Nicholas
    Caravan, Peter
    CHEMPLUSCHEM, 2016, 81 (03): : 274 - 281
12345